论文部分内容阅读
流行病学的调查表明,结核病的患病率和死亡率近些年来有很大下降。但是结核病仍属于传染广泛和发病率较高的慢性传染病。在结核病的防治中,不断寻找抗结核药物至今仍是非常重要。自1966年甲哌力复霉素(利福平“Rifampin”简称Rfp) 问事以来,对结核病的防治又提供了一个有力的武器,但是,由于甲哌力复霉素制药生产工艺较复杂,售价昂贵,再加上临床用药后易产生耐药性,因此在应用上仍受到一定限制。寻找和研究抗菌作用较好、生产工艺简便的、售价低廉的抗结核药物仍然是不断努力的方向。1976年四川抗菌素工业研究所研制成功异丁基哌嗪力复霉素(R76—1)。
Epidemiological surveys show that the prevalence and mortality rates of tuberculosis have dropped dramatically in recent years. However, tuberculosis still belongs to chronic infectious diseases with widespread and high incidence. In the prevention and treatment of tuberculosis, it is still very important to constantly look for anti-tuberculosis drugs. Since 1966, mefenamicin (rifampin “Rifampin” referred to as Rfp) since the question, the prevention and treatment of tuberculosis and provided a powerful weapon, however, due to more complicated mechlorethamine drug production process, Expensive, coupled with easy to produce drug resistance after clinical treatment, so the application is still subject to certain restrictions. Looking for and studying antimicrobial effect is good, the production process is simple, low prices of anti-TB drugs is still the direction of continuous efforts. In 1976, the Sichuan Institute of Antibiotics was successfully developed isobutylpiperazine erythromycin (R76-1).